Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK plc has filed its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, providing audited financial statements for the year ended 31 December 2025. The report is accessible online via the company’s website and the SEC portal, with hard copies and the Notice of Annual General Meeting expected to be available around 25 March 2026.
Shareholders can request free hard copies of the full audited financial statements through GSK’s UK registrar, Computershare Investor Services, or its U.S. ADR depositary, J.P. Morgan’s Computershare Trust Company N.A. This filing fulfills GSK’s New York Stock Exchange disclosure obligations and offers investors detailed visibility into the company’s 2025 financial performance and governance documentation.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines and vaccines that help people get ahead of disease. The group operates across major pharmaceutical and vaccine markets worldwide, positioning itself as a key player in the global healthcare and biopharma industry.
Average Trading Volume: 8,992,413
Technical Sentiment Signal: Buy
Current Market Cap: £83.2B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.